New Queensland office for MTPConnect at TRI

This week we welcome Andrew Bowskill, the newly appointed MTP Connect Director of Stakeholder Engagement for Queensland, to the TRI Building.

In this role, Andrew will promote and facilitate MTPConnect's activities in Queensland - including programs and initiatives that grow and benefit the medical technology and pharmaceutical sector. He will work with stakeholders across various companies, industry associations, research organisations to build medical technology and pharmaceutical capabilities and capacities across the region.

Andrew joins MTPConnect from Medicines Australia, where he was Manager of Industry and Regulatory Policy, engaging with a broad cross section of stakeholders including consumer groups, companies, peak bodies and Commonwealth and State officials. As well as his extensive networks, Andrew brings deep understanding of MTP industry and regulatory policy including R&D policy, intellectual property, trade agreements and biosimilars. Andrew has a Bachelor of Pharmacy from the University of Otago and has held a number of pharmacy roles in Queensland including Clinical Pharmacist, Adult Emergency and Medical Admissions and Planning Unit, Mater Pharmacy Services and Team Leader, Mater Private Hospital Pharmacy.

Through their Growth Centre Project Fund program, MTPConnect supports TRI and Vaxxas in an initiative to establish a flexible and accessible medtech/pharma clinical manufacturing facility to enable the translation of innovative, investigational products into clinical. Listen to a recent podcast episode to hear how TRI and Vaxxas are enhancing MTP skills and manufacturing capabilities.

See the original MTPConnect article here.